Form 4: Nuvalent CEO Trades Shares Under 10b5-1 Plan

Nuvalent, Inc. President and CEO James Richard Porter executed a series of stock transactions on April 6, 2026, under a pre-established Rule 10b5-1 trading plan.

Summary

• James Richard Porter, President and CEO of Nuvalent, Inc., engaged in multiple stock transactions on April 6, 2026.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on December 4, 2025.
• Porter acquired 13,714 shares of Class A Common Stock at $18.93 and 16,286 shares at $27.85.
• He also disposed of a total of 30,500 shares of Class A Common Stock across several transactions at weighted average prices ranging from $102.52 to $105.48.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the CEO is actively trading, the use of a Rule 10b5-1 plan mitigates concerns about insider trading, and the mix of acquisitions and dispositions suggests a balanced approach.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned and potentially non-insider trading related activity.
• Acquisition of shares at lower price points ($18.93 and $27.85) could be seen as a strategic investment by management.
• The CEO's continued involvement and transactions suggest confidence in the company's long-term prospects.

Negatives

• The disposal of a significant number of shares (30,500) at prices around $100+ could be interpreted as a signal of reduced confidence or a desire to diversify by the CEO.
• The weighted average sale prices indicate a substantial value realized from the disposed shares.

Risks

• The disposal of shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market, potentially impacting share price.
• Future stock performance is subject to the inherent risks of the biopharmaceutical industry, including clinical trial outcomes and regulatory approvals.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 4, 2025.
• The price reported is a weighted average price for shares sold in multiple transactions at prices ranging from $102.52 to $103.51, inclusive.
• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the specified ranges upon request.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those under Rule 10b5-1 plans, are common in the biopharmaceutical sector as executives manage personal portfolios while adhering to regulatory guidelines. The dual nature of acquisitions at lower prices and dispositions at higher prices is a typical strategy within such plans.

Stakeholder Impact

• Shareholders: The transactions may lead to short-term market reactions, but the Rule 10b5-1 plan aims to reduce the impact of individual trades.
• Employees: The CEO's actions could influence employee sentiment regarding the company's stock value.
• Management: Demonstrates adherence to regulatory requirements for insider trading.

Next Steps

• The reporting person may continue to execute transactions under the existing Rule 10b5-1 plan.
• The company's future performance will depend on its clinical development pipeline and market reception.

Key Dates

Keywords

Nuvalent, NUVL, Form 4, Insider Trading, Rule 10b5-1, Stock Transactions, CEO, Class A Common Stock, Beneficial Ownership, Securities Exchange Act